Potent P2Y 12 inhibitor monotherapy versus dual antiplatelet therapy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: Rationale and design of the STARS DAPT randomized pilot trial
Publication date: Available online 1 November 2026 Source: American Heart Journal Author(s): Juan F Iglesias, Barbara Stähli, Dik Heg, Alessandro Candreva, Dorian Garin, Maia Muresan, Marco Valgimigli, Marco Roffi
Potent P2Y 12 inhibitor monotherapy versus dual antiplatelet therapy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: Rationale and design of the STARS DAPT randomized pilot trial. // American Journal of Kidney Diseases. – URL: https://www.sciencedirect.com/science/article/pii/S0002870326003108?dgcid=rss_sd_all
Potent P2Y 12 inhibitor monotherapy versus dual antiplatelet therapy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: Rationale and design of the STARS DAPT randomized pilot trial. American Journal of Kidney Diseases. https://www.sciencedirect.com/science/article/pii/S0002870326003108?dgcid=rss_sd_all
“Potent P2Y 12 inhibitor monotherapy versus dual antiplatelet therapy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: Rationale and design of the STARS DAPT randomized pilot trial.” American Journal of Kidney Diseases.
@article{article3304,
title = {Potent P2Y 12 inhibitor monotherapy versus dual antiplatelet therapy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: Rationale and design of the STARS DAPT randomized pilot trial},
journal = {American Journal of Kidney Diseases},
url = {https://www.sciencedirect.com/science/article/pii/S0002870326003108?dgcid=rss_sd_all}
}